CYTK
Cytokinetics, Incorporated · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +18.2% ·
share flow +10.3% ·
net new positions +15.4%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 11.48K | $711,878 | n/a | −1 |
| Q2 2026 | 126 | +7 | 95.69M | $8.15B | +10 | −4 |
| Q1 2026 | 123 | +1 | 87.96M | $5.79B | +8 | −8 |
| Q4 2025 | 121 | -1 | 92.45M | $5.87B | +2 | −2 |
| Q3 2025 | 19 | +2 | 69.14M | $3.80B | +2 | −1 |
| Q2 2025 | 15 | -2 | 62.06M | $2.05B | n/a | −2 |
| Q1 2025 | 14 | +1 | 26.36M | $1.06B | +1 | n/a |
| Q4 2024 | 13 | -1 | 25.19M | $1.18B | n/a | −1 |
| Q3 2024 | 13 | +2 | 19.21M | $1.01B | +2 | n/a |
| Q2 2024 | 11 | n/a | 17.42M | $943.61M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 7.77M | +3.5% | $410.52M | 0.1% | ▲ Add | 2 | SEC ↗ ×8 |
| 2 | T. Rowe Price ✦ | 3.16M | +34.2% | $167.11M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 2.85M | +4.0% | $150.43M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Marshall Wace ✦ | 1.87M | +11.7% | $98.93M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 992.64K | +24.1% | $52.41M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 937.19K | +9.1% | $49.48M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 7 | Fisher Asset Management ✦ | 542.28K | +1.4% | $28.63M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 464.01K | +23.8% | $24.50M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 9 | Two Sigma Investments ✦ | 258.92K | +341.8% | $13.67M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 244.37K | -48.1% | $12.90M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | Millennium Management ✦ | 60.60K | New | $3.20M | 0.0% | New | 1 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 37.36K | +11.8% | $1.97M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 13 | D. E. Shaw & Co. ✦ | 11.79K | New | $622,512 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $3.20M | 0.0% |
| D. E. Shaw & Co. | $622,512 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 437 holders, 145.17M shares, $8.22B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.50K sh · $224,035
Officer, Director · 7.50K sh · $471,600
Officer · 3.50K sh · $214,830
Officer, Director · 7.50K sh · $490,950
Officer · 3.50K sh · $239,015
Officer, Director · 97.93K sh · $6.79M
Director · 1.00K sh · $72,130
Officer, Director · 7.50K sh · $550,800
Director · 1.00K sh · $74,660
Officer · 3.50K sh · $264,110
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology